Press Release

Portola Agrees to Sell to Alexion for $1.41 Billion

May 5, 2020

San Francisco – May 5, 2020 – Cooley advised Portola, a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders, on its agreement to sell to Alexion Pharmaceuticals for $18 per share in cash – a value of $1.41 billion. Jamie Leigh, Ian Nussbaum, Kenneth Guernsey, Robert Jones and Sally Kay led the Cooley team advising Portola on the transaction, which is expected to close in Q3. 

Portola’s commercialized medicine Andexxa (marketed as Ondexxya in Europe) is the first and only approved factor Xa inhibitor reversal agent. It has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding. The acquisition will diversify Alexion’s hematology, neurology and critical care commercial portfolio, creating long-term value for patients and shareholders. 

“In developing and launching Andexxa, Portola has established a strong foundation for changing the standard of care for patients receiving factor Xa inhibitors that experience a major, life-threatening bleed,” Scott Garland, president and CEO of Portola, said in a statement. “Given their enhanced resources, global footprint and proven commercial expertise, we look forward to working with Alexion to maximize the value of Andexxa.”

Cooley has advised Portola since its founding in 2003 in San Francisco and, in 2013, guided the company on its $140 million initial public offering. Portola’s securities trade on the Nasdaq Global Market under the symbol “PTLA.”

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 1,100+ lawyers across 16 offices in the United States, Asia and Europe.


This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.